IBDEI2XW ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,46911,1,4,0)
 ;;=4^N40.0
 ;;^UTILITY(U,$J,358.3,46911,2)
 ;;=^5015689
 ;;^UTILITY(U,$J,358.3,46912,0)
 ;;=N41.0^^179^2339^2
 ;;^UTILITY(U,$J,358.3,46912,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46912,1,3,0)
 ;;=3^Acute prostatitis
 ;;^UTILITY(U,$J,358.3,46912,1,4,0)
 ;;=4^N41.0
 ;;^UTILITY(U,$J,358.3,46912,2)
 ;;=^259106
 ;;^UTILITY(U,$J,358.3,46913,0)
 ;;=N41.1^^179^2339^6
 ;;^UTILITY(U,$J,358.3,46913,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46913,1,3,0)
 ;;=3^Chronic prostatitis
 ;;^UTILITY(U,$J,358.3,46913,1,4,0)
 ;;=4^N41.1
 ;;^UTILITY(U,$J,358.3,46913,2)
 ;;=^186931
 ;;^UTILITY(U,$J,358.3,46914,0)
 ;;=N41.2^^179^2339^1
 ;;^UTILITY(U,$J,358.3,46914,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46914,1,3,0)
 ;;=3^Abscess of prostate
 ;;^UTILITY(U,$J,358.3,46914,1,4,0)
 ;;=4^N41.2
 ;;^UTILITY(U,$J,358.3,46914,2)
 ;;=^270416
 ;;^UTILITY(U,$J,358.3,46915,0)
 ;;=N40.2^^179^2339^9
 ;;^UTILITY(U,$J,358.3,46915,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46915,1,3,0)
 ;;=3^Nodular prostate w/o LUTS
 ;;^UTILITY(U,$J,358.3,46915,1,4,0)
 ;;=4^N40.2
 ;;^UTILITY(U,$J,358.3,46915,2)
 ;;=^5015691
 ;;^UTILITY(U,$J,358.3,46916,0)
 ;;=N40.3^^179^2339^8
 ;;^UTILITY(U,$J,358.3,46916,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46916,1,3,0)
 ;;=3^Nodular prostate w/ LUTS
 ;;^UTILITY(U,$J,358.3,46916,1,4,0)
 ;;=4^N40.3
 ;;^UTILITY(U,$J,358.3,46916,2)
 ;;=^5015692
 ;;^UTILITY(U,$J,358.3,46917,0)
 ;;=N40.1^^179^2339^3
 ;;^UTILITY(U,$J,358.3,46917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46917,1,3,0)
 ;;=3^BPH (enlarged prostate) w/ LUTS
 ;;^UTILITY(U,$J,358.3,46917,1,4,0)
 ;;=4^N40.1
 ;;^UTILITY(U,$J,358.3,46917,2)
 ;;=^5015690
 ;;^UTILITY(U,$J,358.3,46918,0)
 ;;=Z12.5^^179^2339^11
 ;;^UTILITY(U,$J,358.3,46918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46918,1,3,0)
 ;;=3^Screen for Malig Neop of Prostate
 ;;^UTILITY(U,$J,358.3,46918,1,4,0)
 ;;=4^Z12.5
 ;;^UTILITY(U,$J,358.3,46918,2)
 ;;=^5062688
 ;;^UTILITY(U,$J,358.3,46919,0)
 ;;=R97.20^^179^2339^7
 ;;^UTILITY(U,$J,358.3,46919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46919,1,3,0)
 ;;=3^Elevated PSA
 ;;^UTILITY(U,$J,358.3,46919,1,4,0)
 ;;=4^R97.20
 ;;^UTILITY(U,$J,358.3,46919,2)
 ;;=^334262
 ;;^UTILITY(U,$J,358.3,46920,0)
 ;;=R97.21^^179^2339^10
 ;;^UTILITY(U,$J,358.3,46920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46920,1,3,0)
 ;;=3^Rising PSA s/p Treatment for Prostate CA
 ;;^UTILITY(U,$J,358.3,46920,1,4,0)
 ;;=4^R97.21
 ;;^UTILITY(U,$J,358.3,46920,2)
 ;;=^5139228
 ;;^UTILITY(U,$J,358.3,46921,0)
 ;;=D29.21^^179^2340^2
 ;;^UTILITY(U,$J,358.3,46921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46921,1,3,0)
 ;;=3^Benign neoplasm right testis
 ;;^UTILITY(U,$J,358.3,46921,1,4,0)
 ;;=4^D29.21
 ;;^UTILITY(U,$J,358.3,46921,2)
 ;;=^5002093
 ;;^UTILITY(U,$J,358.3,46922,0)
 ;;=D29.22^^179^2340^1
 ;;^UTILITY(U,$J,358.3,46922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46922,1,3,0)
 ;;=3^Benign neoplasm left testis
 ;;^UTILITY(U,$J,358.3,46922,1,4,0)
 ;;=4^D29.22
 ;;^UTILITY(U,$J,358.3,46922,2)
 ;;=^5002094
 ;;^UTILITY(U,$J,358.3,46923,0)
 ;;=E29.1^^179^2340^16
 ;;^UTILITY(U,$J,358.3,46923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,46923,1,3,0)
 ;;=3^Testicular Hypofunction
 ;;^UTILITY(U,$J,358.3,46923,1,4,0)
 ;;=4^E29.1
 ;;^UTILITY(U,$J,358.3,46923,2)
 ;;=^5002754
 ;;^UTILITY(U,$J,358.3,46924,0)
 ;;=N43.3^^179^2340^9
 ;;^UTILITY(U,$J,358.3,46924,1,0)
 ;;=^358.31IA^4^2
